The expression of three well-described MS-associated HLA-I and -II risk alleles (i.e., HLA-A*0301, -DRB1*1501 and -DRB*1301; [50]) by the allogeneic BLCL-GR facilitated simultaneous detection of CD4+ and CD8+ T-cell responses in TCL of HLA-matched MS patients towards endogenously synthesized and processed human cMSAg [42]. The gene discussed is HLA-A; the disease is myeloid sarcoma.